Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Conventus Orthopaedics Inc.

The union of minimally invasive cardiology and orthopedics

This article was originally published in Start Up

Executive Summary

Entering a market dominated by invasive metal plates and screws, the founders of Conventus Orthopaedics Inc., who came from the cardiovascular industry, have adapted the concept of minimally invasive self-expanding stents to the problem of treating distal radius fractures, the most common fracture of the forearm.

You may also be interested in...



New Technologies Drive Growth In Orthopedic Extremities Market

While the mature hips, knees, and spine segments of the orthopedics industry are growing by low single-digit rates, some sectors of the extremity industry are growing by 13% to 14%. START-UP profiles three companies in different sectors of extremities: Conventus Orthopaedics, in the hand and wrist market, Nextremity Solutions, working on devices for the forefoot, and Cartiva Medical, with a cartilage platform and an initial focus on the great toe.

Extremities, Emerging Markets Continue To Top Ortho M&As

With hip and knee joint markets still registering slow to modest growth, orthopedic companies looking to add bulk to their bottom line through mergers and acquisitions have pursued two distinct directions – the extremities and emerging markets.

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel